OR WAIT null SECS
Lonza and Singzyme will use Singzyme’s enzymatic conjugation platform to develop novel bioconjugates.
Lonza and Singzyme, a biotechnology company specializing in developing enzymes for protein ligation, announced a strategic collaboration on Oct. 31, 2022. The goal of this partnership is for the companies to use Singzyme’s enzymatic conjugation platform to develop novel bioconjugates.
The partnership will grant Lonza access to Singzyme’s enzymatic conjugation platform, which is designed to enable the site-specific binding of payloads with peptidic linkers to proteins of interest. In return, Singzyme will gain access to Lonza’s network and expertise in the development and manufacture of bioconjugates.
“Singzyme’s highly-specific conjugation platform represents an attractive addition to Lonza’s Bioconjugation toolbox that includes protein expression, linker and payload manufacturing, manufacturability assessments, de-risking, and bioconjugation,” said Stefan Egli, vice-president and head of Bioconjugates, Lonza, in the release. “Its implementation into our offering will further increase our bioconjugation repertoire and provide reliable and selective conjugation solutions for our customers aiming to develop novel bioconjugates.”
“The collaboration between Lonza and Singzyme will provide Lonza’s customers with access to a one-stop technology platform allowing for rapid site-specific bioconjugation including dual payloads, with fully controllable drug-to-antibody ratio, while preserving antibody activity,” said Abbas El Sahili, chief technology officer, Singzyme, in the release. “We foresee that this collaboration will significantly shorten the [antibody drug conjugate] development timeline and bring a wealth of novel drugs faster to the clinic for the benefit of cancer patients.”